Our data demonstrate that NEDD9 is capable of restraining the DNA damage response to platinating (such as cisplatin) and other cross-linking agents, such as ultraviolet irradiation, by restraining ATM and ERCC4 kinases signaling in multiple lung cancer cell models, which defines NEDD9 as a candidate modifier gene in this context. This evidence concerns the gene ATM and lung cancer.